After a disappointing H1 MDxHealth will have to work hard to achieve its 55%-75% sales growth guidance. With a historically stronger H2, we are confident that it has now assembled all the elements to fuel the growth of its prostate cancer test ConfirmMDx from the H2 / 2017. Included in key clinical guidelines, ConfirmMDx is now reimbursed by >60 public and private payers, as well as the subject of a number of service agreements with substantial US healthcare networks. A near doubling of the sale ....
08 Sep 2017
Fuelled for take off
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fuelled for take off
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
08 Sep 2017 -
Author:
Chris Redhead -
Pages:
11
After a disappointing H1 MDxHealth will have to work hard to achieve its 55%-75% sales growth guidance. With a historically stronger H2, we are confident that it has now assembled all the elements to fuel the growth of its prostate cancer test ConfirmMDx from the H2 / 2017. Included in key clinical guidelines, ConfirmMDx is now reimbursed by >60 public and private payers, as well as the subject of a number of service agreements with substantial US healthcare networks. A near doubling of the sale ....